Abundant evidence has accumulated indicating that neoplasms induced by various oncogenic viruses possess specific transplantation antigens (for review see reference 1), common for different tumors induced by the same virus. In analogy with results obtained in experiments with other viral tumors, a strong resistance against isotransplantation of mouse sarcomas, induced by the Schmidt-Ruppin strain of Rous sarcoma virus (RSV-SR), can be built up by pretreatment with allogeneic or syngeneic Rous sarcoma cells (2, 3). However, in contrast to the other viral tumor systems, attempts to demonstrate a virusinduced transplantation resistance (VIR) after inoculation of RSV-SR into adult mice have given negative or inconclusive results (3).
Further experiments seemed desirable in order to elucidate the immunological events in the course of induction of primary Rous sarcomas in mice. Preliminary studies have indicated that the newborn infected mice which do not develop primary Rous sarcomas exhibit a specific transplantation immunity to Rous sarcoma isografts (8) . The present paper fully confirms this result. Furthermore the studies have been extended to the mice which do develop primary tumors. The results of parallel investigations on specific transplantation immunity and development of virus-neutralizing humoral antibodies are reported.
Material and Methods
Mice.--The inbred strains A/Sn, its coisogenic resistant sublines A.CA and A.SW, as well as C3H and Fl-hybrids between these strains and DBA/2, CBA, and C57BL/K1 were used. The breeding and maintenance of the animals have been described previously (3, 6) .
Tumor Induction.--For induction of primary tumors newborn mice, not older than 2 days, were injected subcutaneously with 0.05 cc of a crude cell suspension of Rous chicken sarcoma (strain RSV-SR) prepared (1:5) in a balanced salt solution (4) . It was attempted to localize the inocula to the proximal part of the right hind leg in order to obtain tumors at an operable site.
When suitably located primary tumors had reached a diameter of 5 to 10 mm, they were extirpated under ether anesthesia, either by amputation of the tumor-bearing leg or by direct excision of tumors on the back, that could be loosened from the spine and back muscles.
Sham operations on syngeneic control mice were performed in parallel either by amputation of a leg or by an incision on the back. Mice developing no palpable primary tumors after inoculation of RSV-SR when newborn were used in the transplantation tests at various ages.
Immunization with Autologouz or Syngeneic Tumor Cdls.--In the experiments designed to investigate whether it is possible to induce a transplant immunity in the primary tumorbearing animals the procedure was similar to that previously used in experiments with methylcholanthrene-induced sarcomas (9) . Mter extirpation the primary tumor was dissected free under sterile conditions, and part of the tumor was trypsinized. Known numbers of trypan blue unstained tumor cells (10) were inoculated subcutaneously into syngeneie preirradiated recipients, in order to determine the cell number necessary for progressive tumor growth in 100% of irradiated controls (= Dmx) and in order to keep the tumor in passage. Another part of the tumor was used for immunization. 0.1 cc of an irradiated (8000 R) crude cell suspension was inoculated subcutaneously into the autochthonous host and 5 to I0 shamoperated previously untreated syngeneic mice. The inoculations of X-irradiated cells were repeated three times at biweekly intervals, using tumor material from a frozen part of the original tumor or from the first passage of this tumor.
Transplantation tests were performed by subcutaneous inoculation of mechanically prepared or trypsinized cell suspensions.
The transplantability of primary tumors to the autochthonous hosts immediately after extirpation of the tumors in question, was tested with the use of a crude cell suspension prepared by thorough mincing of the tumor tissue in balanced salt solution and filtration through double gauze, whereafter the suspension was inoculated subcutaneously undiluted or diluted 1:10 or 1:100, respectively. In this way an attempt was made to inoculate a suitable test dose, as there was no opportunity to determine the exact minimum cell dose necessary for progressive growth in untreated controls (= Dm). The test cell dose was deposited at a site distant from the recently operated area in order to avoid confusion with a recurrence of the original tumor. Mice presenting such recurrences were omitted. Previously untreated syn-NILS JONSSON AND HANS OLO~F SJOGREN 489 geneic mice were sham operated in parallel with the autochthonous hosts and served as con-
trois.
As it seemed also desirable to use critically determined test cell doses and to use recipients that had recovered from the operation with certainty, other experiments included the same type of recipients, inoculated at various times after the extirpation with known numbers of trypan blue unstained tumor cells. The test tumors were previously examined syngeneic or autologous Rous tumors with known Dm and with established specific transplantation antigenieity (3) . Litter mates of the experimental animals, inoculated with a suspension of normal chicken tissue (liver, skeletal muscle) when newborn and sham-operated in parallel with the tumor-bearing mice, were used as controls.
When testing rcdpients, immunized with irradiated autochthonous tumor cells after extirpation of the primary tumor, known numbers of trypsinized tumor cells from the autochthonous tumor or a syngencic tumor with establishcd antigenicity were inoculated.
Animals, developing no primary tumors within 2 months after recdving an inoculation of Rous chicken sarcoma tissue when newborn, were tested with known numbers of tryp~ini~l syngeneic tumor cells deriving from tumors with established antigenicity. Litter mates inoculated with normal chicken tissue or syngeneic mice, inoculated as adults with 0.25 cc of the same Rous chicken sarcoma suspension, were used as controls.
M~se serum was obtained from blood collected by puncturing the retroorbital sinus with a glass capillary.
Antidral anffbodles were assayed according to the focus-neutralizing technique of
Rubin et al. (11, 12) as described previously (3) . Each test included 2 mouse serum dilutions (1:2, 1:3, or 1:$, depending upon the amount of serum available, and 1:20 or 1:25, respectively). Chicken anti-RSV-SR serum served as control serum.
Irradiation Procedures.--Groups of mice received total body X-irradiation 24 hr prior to the test in doses of 300 R to animals up to 2 wk of age and 350 to 400 R to older animals. Tumor cells were irradiated with a dose of 8000 R. X-rays were generated at 200 kv, 15 ma and filtered by 0.5 mm AI + 0.5 mm Cu for the mice and by 1 mm AI for the tumor cells.
The test animals were inspected once a week. Developing tumors were measured by caliper and the geometrical mean of 3 diameters was estimated.
RESULTS

Specific Transplantation Immunity of Mice Pretreated with RSV-SR when Newborn but Developing No Primary Rous Sarcornas.--Known numbers of
trypsinized Rous tumor cells were inoculated into the following categories of genetically compatible recipients: (a) mice inoculated when newborn with 0.05 ml of an 1:5 suspension of Rous chicken sarcoma (RSV-SR), but developing no palpable primary tumors before the test (2 to 5 months); (b) litter mates of the previous group of mice, pretreated when newborn with a subcutaneous inoculation of normal chicken tissue; and, as controls (c) mice pretreated as adults with 4 to 6 allografts of Rous mouse sarcomas with known specific antigenicity; and (d) untreated mice. The mice were either unirradiated or preirradiated 24 hr prior to test. The test tumor cell doses were given subcutaneously on the abdomen or the breast in order to avoid confusion with later appearing primary tumors. The doses given were chosen on the basis of previously determined cell doses required by each test tumor to grow progressively in 100 % of untreated mice, unirradiated (= Din) or preirradiated (= Dmx). § Means prolonged latency period and slower tumor growth than in the control groups.
[[ Means the approximate minimum cell number required for progressive tumor growth in untreated controls, unirradiated (= Din) or preirradiated (= Dmx).
Only mice developing no primary tumors during the test period are included in the table. Unirradiated mice, pretreated with normal chicken tissue show some resistance, which cannot be detected after preirradiation and thus probably is nonspecific. Recipients pretreated when newborn with RSV-SR show a clearcut immunity to cell doses, corresponding to Dm and 10 x Dm (I)mx and 10 x Dmx, respectively). The immunity is expressed as a reduced frequency of takes in comparison with mice pretreated with normal tissue. The resistance is not abolished by whole body X-irradiation prior to the challenge. The summarized results reveal a highly significant difference between preirradiated mice pretreated with Rous chicken sarcoma and mice pretreated with normal chicken tissue (X ~ for the ])mx dose = 21.72; P < 0.001~'-~). The controls allografted with Rous tumors showed the expected immunity.
The resistance of the RSV-SR pretreated mice is apparent not only from the take figures but also from the tumor growth curves (Figs. 1 a and 1 b). The figure shows the prolonged latency period and slower tumor growth of the RSV-SR pretreated mice in comparison to animals pretreated with normal chicken tissue. The resistance is thus of a higher magnitude than that demonstrated in the above table.
In another series of experiments mice, pretreated as adults with a subcutaneous inoculation of 0.25 cc of the same Rous chicken sarcoma suspension as newborn mice received, were tested parallelly for specific transplantation immunity. The results are summarized in Table II , in which two different time intervals between the RSV-SR inoculations and the tests are noted. Also the recipients pretreated with RSV-SR as adults were in one experiment (test tumor RS57A) found to be resistant even after preirradiation before the test. This resistance was demonstrated 2 wk after the RSV-SR inoculation, while simultaneously tested mice, infected 4 wk previously, were not resistant. No transplantation immunity could be demonstrated in the other 3 experiments with preirradiated recipients. The isograft resistance of mice inoculated with RSV-SR when newborn was clearly demonstrable also in these experiments, although it was not as strong as in the above mentioned series of experiments (X 2 = 5.74, calculated for the Dmx dose in comparison with untreated controls; 0.02 :> _P > 0.01=). the approximate Dm could be determined for each tumor at the end of the observation period on the basis of the appearance and growth of the test tumors in the controls. The doses given to the autochthonous hosts correspond to 0.1 X Dm, Dm and 10 X Dm, respectively. The results are grouped in Table III according to these cell doses. Except in 2 cases no transplantation immunity could be demonstrated in the primary autochthonous hosts. The latency periods and tumor growth curves in these animals did not differ from what was observed ROIYS SARCOMA VIRUS TUMORIGENESIS in the controls given the same cell dose. Two of the tumors, randomly chosen, were tested for specific transplantation antigenicity by isografting to mice, previously allografted with other Rous tumors, and for the presence of the viral genome by inoculation into chickens; both the tumors contained the RSV-SR and were specifically antigenic as well.
Transplantation Immunity Tests in Primary Turrwr-Bearing Mice after Extirpation of the Primary
One of the resistant autochthonous hosts proved resistant also at a repeated transplantation test.
In another series of experiments known numbers of tumor cells deriving from Rous tumors with previously determined Dm and Dmx doses were used to test for transplantation immunity at different times subsequent to the extirpation of the primary tumors. In order to detect a possible tolerance against the specific transplantation antigens the experiments also included low cell doses (0.01 X I)m and 0.1 X Din). The Dm (Dmx) and 10 X Dm (10 X Dmx) were given to unirradiated and preirradiated recipients in order to detect a possible transplantation resistance. The results collected in Table IV and the rate of tumor growth demonstrate no significant difference between the operated primary tumor-bearing mice on one hand and untreated controls or sham-operated controls, pretreated with normal chicken tissue on the other. A very weak resistance of the operated, primary tumor hosts cannot be excluded, however, since the frequency of takes was slightly reduced in most experiments. In the RWE experiment the operated mouse was shown to be resistant against the 495 10 X Dm dose of its own autologous tumor. No increased frequency of takes was noted for the lower cell doses in mice with extirpated primary tumors. Thus, there was no indication of a specific tolerance. cells is radioresistant (3) irradiated tumor cells were used for immunization. Table V summarizes the results of the transplantation tests performed on the operated autochthonous hosts and sham-operated syngeneic mice, pretreated in parallel with irradiated tumor material. In most experiments the original tumors were used both for immunization and testing, but in one case the tumor was lost and replaced by a syngeneic Rous tumor of known antigenicity.
Tests for Transplantation Immunity in Operated Primary
Tests were performed with 15 autochthonous hosts, of which 3, however, had recurrences of the original tumor and were excluded. In both the experiments performed on unirradiated recipients, in which the Dm dose was used for 
testing, the autochthonous hosts were resistant as well as the syngeneic mice pretreated in parallel, while with the third tumor no resistance could be shown against the l0 X Dm dose. Four out of 5 immunized autochthonous hosts, preirradiated before the test challenge, were also completely resistant against the I)mx dose, while in one animal no resistance was demonstrable although the pretreated syngeneic mice were resistant. A complete resistance of the preirradiated autochthonous hosts against the 10 X Dmx dose was also demonstrable in 2 out of 5 animals. In two other experiments the appearing test tumors showed a prolonged latency period and slower tumor growth in the autochthonous hosts and immunized syngeneic mice as well, as compared to untreated controls (Figs. 2 a and 2 b) . In the remaining case the pretreated syngeneic mice but not the autochthonous host were resistant against the 10 X Dmx dose.
Tests for Virus-Neutralizing Activity in the Sera of Mice Used in the Transplantation Experiments.--The results are summarized in Table VI . Only sera of preirradiated mice are included, with the exception of the group tested directly after extirpation of the primary tumors, in which no preirradiafion was performed. Among the mice resistant against tumor induction after RSV-SR inoculation in the neonatal period, only 2 developed neutralizing activity, and none of these animals revealed any isograft resistance. The other 28 sera tested contained no virus-neutralizing activity irrespective of whether the mice were transplantation resistant or not. One of the mice developing primary tumors had a fiter of 1:3 and was not resistant on autografting. The other 5 sera obtained from mice with primary tumors were negative. Three out of 4 operated primary tumor-bearing mice as well as syngeneic controls, pretreated with irradiated tumor cells had no demonstrable virus-neutralizing activity. Nor could such activity be found after RSV-SR inoculation into adult animals, as was previously found (3).
DISCUSSION
The present investigation fully confirms the results of preliminary experiments (8) that mice inoculated during the first few days of life with living RSV-SR chicken sarcoma cells and remaining free from primary tumors thereafter, are specifically immune to Rous sarcoma isografting. That an immunization against possible specific chicken tumor antigens is of no importance for induction of this immunity is indicated by the finding that mice treated with one dose of Rous chicken sarcoma cells when newborn develop a stronger immunity than animals treated, even repeatedly, as adults. Adult mice would be expected to react more vigorously than newborns if the antigens were fully expressed in the inoculated chicken sarcoma cells. Therefore it seems more likely that the specific transplantation immunity is induced by Rous virus released from the inoculated chicken sarcoma cells. A specific transplantation immunity against polyoma tumors has previously been demonstrated in mice inoculated with polyoma virus when newborn without developing any primary tumors (5, 13) . On the other hand inoculation of SV40 virus into newborn hamsters does not induce any isograft immunity against SV40-induced tumors irrespective of whether primary tumors later develop or not (7).
The differences among the mentioned viruses in their capacity to induce transplantation immunity might be due to time factors. Xenografted Rous chicken sarcoma cells are known to survive several days in newborn mice and rats (14) , permitting a prolonged release of virus. This might lead to the induction of RSV-SR specific transplantation antigens in a large number of cells at a time when the mice have reached immunological competence to react against these antigen(s). The lack of immunization of hamsters against the specific transplantation antigen(s) of SV40 tumors after inoculation of a cellfree SV40 virus preparation, might be due to the induction of the specific antigen(s) in an insufficient number of cells to give immunization. A prolonged virus infection comparable to the RSV-SR infection after inoculation of living chicken Rous sarcoma cells might very well give rise to an immunity also in the SV40 system. The immunity demonstrable after a repeated SV40 virus inoculation (7) might be explained in this way. Finally, in the case of polyoma virus, an active multiplication until the time of immunological maturation, is indicated by the high titers of hemaggiufinating antibodies in the sera of mice which have been inoculated with polyoma virus when newborn (13) . Thus, it is understandable that a specific immunization can take place against the polyoma specific tumor antigen.
Tests for RSV-SR-neutralizing antibodies in the sera of newborn-infected mice gave negative results in most cases. This cannot be taken as an indication of a specific tolerance to the RSV-SR antigen or the absence of exposure to the viral antigen at an immunologically mature age, since it has been reported previously that even repeated RSV-SR doses given to adult, immunologically competent mice regularly do not induce any detectable antiviral antibodies (3) .
The antiviral activity demonstrated in a few sera of newborn infected mice indicated that at least in some cases the virus persisted in the animal up to the time when immunological competence had developed. Since positive titers were found in mice developing primary tumors and in the tumor negative ones as well, it seems to be no correlation between the detected antiviral immune response and tumor development.
As has been reported previously (3) there is no positive correlation between the occurrence of antiviral serum activity and isograft immunity and thus no indication of an identity between the antigens of the mature virus particle and the transplantation antigen(s).
The rather strong isograft immunity of mice, resistant to RSV-SR primary tumor induction raised the question of the immunological status of the mice which are sensitive to tumor induction. Are also these animals immunized against the RSV-SR specific transplantation antigen(s) or is the development of primary tumors linked with a tolerance to these antigens developed as a result of antigen exposure during the period of immunological immaturity?
In order to study these questions the primary tumors had to be extirpated since primary Rous sarcomas usually grow rapidly and would otherwise have interfered with the experiments performed. Tests for transplantation immunity against autologous tumor cells, performed immediately after the extirpation of the primary sarcomas gave no indication of any resistance in 9 of the 11 tested autochthonous hosts, while 2 were resistant (1 of them also on a repeated test).
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The test cell doses must be approximate in this type of experiments and it is always difficult to rule out completely the possibility that the extirpation of the tumor might affect the animal differently from the sham operation in some respects. Therefore well known syngeneic test tumors were used for further tests at various intervals after operation. No clear-cut transplantation immunity could be demonstrated, neither in unirradiated nor in preirradiated operated mice although a very weak resistance could not be excluded. Nor could any tolerance to the transplantation antigen(s) in the form of increased frequency of takes with low test cell doses be demonstrated. It might be objected that tolerance could have subsided after removal of the antigenic stimulus at operation, but at least in the first test in Table IV (test tumor RSC) this could not be the case, since the test was performed immediately after the extirpation.
Also these results, obtained with mice which had developed primary Rous sarcomas are different from those reported for SV40 tumors. Deichman et al. (7) , found that hamsters bearing primary SV40 tumors were immune to established SV40 tumor challenge, obviously due to the immunizing capacity of the primary tumor, while no immunity or tolerance was demonstrable during the induction period. It is possible that the development of primary Rous tumors is connected with a resistance too weak to be detected in the transplantation tests. The possible role of an enhancement phenomenon as a result of the presence of large amounts of humoral antibodies in the primary tumor host should be taken into account. The present experiments permit no conclusion on this point. Finally, an unspecific depression of the immune reaction of the primary tumor host, e.g., by toxic products from the rather large primary tumors, might also be considered as an explanation for the absence of any clear immunity.
Similar tests for specific immunity against antigenic, methylcholanthreneinduced mouse sarcomas in the operated autochthonous hosts have also given negative results in pre]imlnary experiments (15) .
The results of serial treatment of operated, primary tumor-bearing hosts with irradiated autologous or syngeneic tumor material clearly show that it is possible to immunize these animals against the tumor-specific transplantation antigen(s). This is in accordance with the previous finding that a state of isograft immunity can be built up against methylcholanthrene-induced sarcomas by a similar treatment with irradiated autologous tumor cells (9) . The results fit well also with the absence of any demonstrable tolerance to the specific cellular antigen(s) in the primary tumor hosts when tested without postoperative immunization. If it existed, such a tolerance would have been expected to be maintained by the pretreatment as would probably an immunological enhancement, which thus also seems less likely. However, a possible partial tolerance might be shifted into immunity by removal of the tumor and pretreatment with irradiated tumor cells. Another explanation might be the existence of a very weak resistance, not detectable in direct transplantation tests, but strengthened by the pretreatment.
The finding (7, 16 ) that SV40 tumorigenesis can be prevented in hamsters infected when newborn by pretreatment during the latency period with SVdO virus or SV40 tumor cells indicates that tumor induction occurs in the absence of any tolerance in that system.
The successful immunization of autochthonous hosts against the Rous mouse tumor antigen(s) also definitely rules out the possibility that isoantigenic heterozygosis might have been responsible for the allo-or isograft-induced transplantation immunity of earlier experiments (2, 3) .
It is tempting to conclude from the results presented that the development of primary sarcomas is prevented in some mice that have been infected with RSV-SR when newborn, because of a successful immunization against the RSV-SR specific transplantation antigen(s). Whether the weak or lacking immune response of mice sensitive to tumor induction is a cause or a consequence of the tumor development cannot be definitely settled at present. The fact that these animals could be immunized indicates that there is no primary immunological defect of the hosts and that the primary hosts are probably not immunologicaUy tolerant to the RSV-SR specific transplantation antigen(s).
SUMMARY
Tests for transplantation immunity and for the occurrence of virus-neutralizing serum antibodies were performed on mice, inoculated when newborn with the Schmidt-Ruppin strain of Rous sarcoma virus (RSV-SR). Mice developing no palpable primary sarcomas showed a clear-cut resistance against the isografting of established specifically antigenic Rous tumors. Transplantation tests performed on primary tumor hosts after extirpation of the tumors revealed neither any clear-cut immunity nor tolerance to the specific transplantation antigen(s). Serial pretreatment of operated primary tumor animals with irradiated autologous or syngeneic tumor cells resulted in a clear-cut transplantation immunity. Virus-neutralizlng activity was only found in a few sera from newborn infected mice, and in these cases there was no positive correlation with the transplantation immunity.
It seems probable that a successful immunization against the RSV-SR specific transplantation antigen(s) prevents the development of primary tumors. There is no indication of any tolerance to this antigen in connection with the induction of primary tumors. 
